Efficiency in clinical research: Assessment in vitro of potential anti-thrombotic drug interactions

Coronary Artery Disease

Volumn 15, Issue 3, 2004, Pages 177-181

  Schneider, David J ^a,b   Whitaker, Deborah A ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Anticoagulant; Antiplatelet; Drug interaction; in vitro; Testing

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; RECOMBINANT NEMATODE ANTICOAGULANT PEPTIDE C2; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL RESEARCH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE FUNCTION;

ADULT; ANTICOAGULANTS; ASPIRIN; BLOOD COAGULATION; BLOOD PLATELETS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 2342514765     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200405000-00007     Document Type: Article

References (19)

1. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108:2697-2703.
2. Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K. Thromboxane A (2) synthase inhibitor enhanced anti-thrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding. Eur J Pharmacol 2001; 417:217-222.
3. Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost 2001; 85:309-313.
4. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003; 4:423-459.
5. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 2003; 254:313-321.
6. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104:181-186.
7. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75:559-562.
8. Ammar T, Scudder LE, Coller BS. in vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95:614-617.
9. Ambrose JA, Hawkey M, Badimon JJ, Coppola J, Geagea J, Rentrop KP, et al. In vivo demonstration of an anti-thrombin effect of abciximab. Am J Cardiol 2000; 86:150-152.
10. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91:334-336.
11. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, et al. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86:651-659.
12. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84:203-207.
13. Holmes MB, Kabbani SS, Terrien CM, Watkins MW, Sobel BE, Schneider DJ. Quantification by flow cytometry of the efficacy of and inter-individual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coron Artery Dis 2001; 12:245-253.
14. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002; 90:112-114.
15. Danzi GB, Capuano C, Sesana M, Baglini R. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Res Opin 2003; 19:28-33.
16. Vlasuk GP, Bradbury A, Lopez-Kinninger L, Colon S, Bergum PW, Maki S, et al. Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. Thromb Haemost 2003; 90:803-812.
17. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 (Suppl 2):24-38.
18. Holmes MB, Schneider DJ, Hayes M, Sobel BE, Mann KG. A novel bedside, tissue factor-dependent clotting assay permitting improved assessment of both anti-thrombotic and antiplatelet therapy. Circulation 2000; 102:2051-2057.
19. Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, et al. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thromb Thrombolysis 2001; 12:165-169.